The revenue forecast by Esperion Therapeutics is a critical financial metric that investors closely monitor. The inclusion of $20M in non-cash expenses for stock compensation is significant but does not directly impact cash flow, which might be viewed positively by investors. The projection indicates growth and operational progress, likely leading to a positive short-term impact on ESPR's stock price.